News | January 10, 2008

Next Generation of Aspirin Absorbs through Mouth Lining

January 11, 2008 - The latest advancement in aspirin is “Fasprin,” an 81mg tablet that enters the bloodstream through the lining of the mouth after rapidly dissolving on the tongue, which recently launched by Improvita Health Products.

A Fasprin tablet quickly dissolves on the tongue in three to five minutes, enabling the aspirin to enter the blood stream faster than conventional aspirin, which breaks down in the stomach. Clinical trials are currently underway to compare the efficacy of Fasprin with that of enteric-coated aspirin and determine how quickly the dosage reaches the bloodstream.

The company said the ability for aspirin to rapidly enter the blood stream has far-reaching advantages for heart attack and stroke sufferers, whose best line of defense at the first sign of an attack is immediately taking aspirin. Aspirin has been proven to stop blood platelets from sticking together, which reduces the chance for blood clots to form and block arteries.

The low-dose aspirin can be used by people who are on an aspirin regimen as a preventative measure against heart attack and stroke. The company said it is ideal for people who have trouble swallowing conventional aspirin, or experience gastric irritation

For more information: www.improvita.com/Fasprin-news, www.Fasprin.com

Related Content

Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals | May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals | April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
Overlay Init